Reassessing Novo Nordisk's Valuation Anchor: From Alzheimer's Failure to Amycretin's Rise

The following day, the company released positive Phase II clinical data for its next-generation dual-target drug Amycretin, leading to a 4.65% stock rebound.

This stock fluctuation has prompted further market scrutiny of the company's R&D pipeline structure and long-term investment value.

The results of two large Phase III clinical trials, EVOKE and EVOKE+, showed that oral semaglutide did not achieve statistical significance in primary endpoints. This five-year study, involving billions of dollars and 3,800 patients, ultimately failed to prove the drug could slow Alzheimer's progression.

From a fundamental perspective, the impact of this Alzheimer's Phase III study failure should be viewed on two levels:

– Novo Nordisk's current profits and cash flow still heavily rely on its GLP-1 business in diabetes and obesity, with core products Ozempic and Wegovy showing stable sales.

– The Alzheimer's indication was previously only in the R&D stage and had not contributed any actual revenue. In cash flow discounting or sum-of-the-parts valuation models, it should have been viewed as a high-risk, high-potential return "option."

In other words, this failure is more like cutting off part of the market narrative's imagination space rather than shaking the core foundation of the company's existing profitability.

– After the "GLP-1 can do anything" narrative was widely accepted, the market was willing to pay a considerable valuation premium for the grand vision of "Alzheimer's + Cardiovascular + Metabolic Comprehensive Management." The failure of the Phase III clinical trial effectively cooled down the overheated narrative of "GLP-1 as a panacea across multiple system diseases."

The key is that this is a minor shift in valuation logic, not a collapse of the company's business model and pipeline prospects.

Just one day after the Alzheimer's setback, Novo Nordisk announced positive Phase II data for its next-generation drug Amycretin.

As a dual agonist targeting both GLP-1 and amylin receptors, Amycretin showed impressive results in Phase II clinical trials. Data revealed that the drug achieved excellent effects of 1.8% reduction in HbA1c and 14.5% weight loss over 36 weeks.

Amycretin's positive data sends a clear signal to the market: Novo Nordisk not only has established GLP-1 drugs but also upgraded iterative products that can take over. This provides a key asset for the company's long-term competition with Eli Lilly.

To understand Novo Nordisk's true value, it can be viewed as an asset composed of three layers:

Foundation Layer: Existing GLP-1 Diabetes and Obesity Drugs

– Semaglutide remains a global blockbuster in the metabolic field, with greatly expanded market accessibility due to recent price reduction agreements with the U.S. government. It will remain the company's unshakeable cash cow business for the next three to five years.

Mid-term Layer: Oral Formulations and Indication Expansion

– Oral semaglutide is expected to be approved by year-end, further improving patient compliance. Meanwhile, the company's indication expansions in cardiovascular, kidney disease, and metabolic syndrome continue to broaden semaglutide's application boundaries and market potential.

Long-term Layer: Multi-target Drug Iteration Upgrades

– Amycretin has become Novo Nordisk's fastest-progressing potential competitor. The pipeline also includes triple agonists like GLP-1/GIP/GGG (introduced with United Pharma) and GLP-1/GIP/Amylin. These arrangements ensure the company's competitiveness in medium to long-term market upgrades.

The battle between Novo Nordisk and Eli Lilly in metabolic diseases is entering a new phase, with Novo Nordisk currently at a slight disadvantage.

Eli Lilly recently became the first pharmaceutical company to surpass $1 trillion in market value. Its weight loss drug Zepbound quickly surpassed Novo Nordisk's Wegovy after launching in late 2023. Lilly's Q3 financial report showed that its diabetes drug Mounjaro and weight loss drug Zepbound contributed a combined $10.1 billion in revenue, more than doubling year-over-year.

Meanwhile, Novo Nordisk's semaglutide sales growth has gradually slowed, and the company has lowered its revenue guidance three times this year.

Facing fierce competition, Novo Nordisk's market focus should be on continued progress in the metabolic field and whether pipeline iterations can rebuild competitive advantages in the long-term game. Amycretin represents the company's future direction, but the road ahead remains challenging in the face of Eli Lilly's strong R&D pipeline.

Novo Nordisk's real challenge lies in how to reshape its growth engine amid intensifying competition with Eli Lilly. Amycretin represents the company's future, and whether it can still support revenue growth acceleration and profit expansion in the next-generation GLP-1 drug competition remains the core focus.

However, the road ahead remains challenging in the face of Eli Lilly's strong R&D pipeline.